[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
September 15, 2015

Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk—Reply

Author Affiliations
  • 1Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, the Netherlands
  • 2Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
JAMA. 2015;314(11):1177-1178. doi:10.1001/jama.2015.9719

In Reply Drs Wagner and Jessen disagree with our conclusion that participants with SCI do not have an increased risk for AD compared with cognitively normal participants. We think that this conclusion is justified because participants with SCI had a similar prevalence of amyloid positivity, the pathological hallmark of AD, as cognitively normal participants.

Wagner and Jessen argue that a meta-analysis1 found that SCI was associated with an increased risk for dementia. However, the outcome measure used in that study was any type of dementia, and therefore it is unclear whether this finding also applies to AD-type dementia.